Episode Details

Patient Square Capital makes a significant investment in Nektar Therapeutics, acquiring over 2% of their shares, valued at nearly $12 million. This move is driven by Nektars promising eczema treatment, rezpegaldesleukin, which has shown impressive results in clinical trials. Nektars innovative approach to manipulating cytokines for immune system boosting, particularly for cancer and autoimmune diseases, has caught the attention of Patient Square. With plans to move rezpegaldesleukin into larger phase three studies, Patient Squares early investment in Nektar could yield significant returns, highlighting the potential upside and risks in biotech investments.

Support the show:
Get a discount at https://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/342d9a3ba2548193